5 – MS Relapses During Natalizumab Therapy Traced to Drug’s Greater Impact on Regulatory T-cells
Natalizumab (Tysabri) harnesses multiple sclerosis (MS) activity by targeting CD49, a molecule on the surface of immune cells. Now, researchers found that the drug reduces the factor on regulatory T-cells to a greater extent than on inflammatory T-cells — a mechanism that might explain disease exacerbation during treatment.
Read full article here: http://bit.ly/1VRIhbE